ArticleBMC pregnancy and childbirth2026
Cerebral venous thrombosis during pregnancy and the puerperium in the setting of hyperhomocysteinemia and methylenetetrahydrofolate reductase c.677 C > T polymorphism.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesCerebral venous thrombosis (CVT) is an uncommon but serious complication of pregnancy and the puerperium that arises in a physiologically hypercoagulable milieu. Hyperhomocysteinemia (HHcy) is a recognized metabolic risk factor for venous thrombosis, and common variants in the methylenetetrahydrofolate reductase (MTHFR) gene may influence homocysteine metabolism. However, the specific interplay between MTHFR variation, HHcy, and pregnancy-associated CVT remains insufficiently defined. This case series explored the clinical relevance of HHcy in obstetric CVT in the presence of the common MTHFR c.677 C > T polymorphism.
methodsWe conducted a retrospective single-center case series of four pregnant or postpartum patients with imaging-confirmed CVT, elevated plasma homocysteine, and documented MTHFR c.677 C > T genotypes. Clinical, radiological, laboratory, treatment, and short-term follow-up data were reviewed.
resultsTwo patients were homozygous (TT) and two heterozygous (CT) for MTHFR c.677 C > T. All four patients had dural venous sinus thrombosis and elevated homocysteine at presentation. TT carriers showed higher homocysteine levels and appeared to have more severe neurological manifestations, including hemorrhagic venous infarction and generalized tonic-clonic seizures. CT carriers also had substantial thrombotic burden but showed comparatively less severe neurological involvement overall, although one experienced a prolonged seizure. All patients received therapeutic anticoagulation, with endovascular intervention in selected severe cases, together with folate, vitamin B₆ and B₁₂ supplementation. Homocysteine normalized in all patients by one month, accompanied by early clinical improvement.
conclusionsIn this case series, HHcy was observed in all four patients with pregnancy- or puerperium-associated CVT and the MTHFR c.677 C > T polymorphism, while higher homocysteine levels and more severe neurological manifestations were observed in the two TT carriers. These observations are exploratory and hypothesis-generating and do not support changes in routine homocysteine screening, MTHFR genotyping, or standard CVT management. Larger prospective multicenter studies are required to clarify the relationships among genotype, metabolic phenotype, and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.